These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 628226)

  • 1. Deferoxamine-chelatable iron in hemochromatosis and other disorders of iron overload.
    Baldus WP; Fairbanks VF; Dickson ER; Baggenstoss AH
    Mayo Clin Proc; 1978 Mar; 53(3):157-65. PubMed ID: 628226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of liver iron content in 271 patients: a reevaluation of direct and indirect methods.
    Brissot P; Bourel M; Herry D; Verger JP; Messner M; Beaumont C; Regnouard F; Ferrand B; Simon M
    Gastroenterology; 1981 Mar; 80(3):557-65. PubMed ID: 7450446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum ferritin, free erythrocyte protoporphyrin, and urinary iron excretion in patients with iron disorders.
    Walsh JR; Fredrickson M
    Am J Med Sci; 1977; 273(3):293-300. PubMed ID: 868919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron overload disorders: natural history, pathogenesis, diagnosis, and therapy.
    McLaren GD; Muir WA; Kellermeyer RW
    Crit Rev Clin Lab Sci; 1983; 19(3):205-66. PubMed ID: 6373141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic efficacy of tests for the detection of iron overload in chronic liver disease.
    Valberg LS; Ghent CN; Lloyd DA; Frei JV; Chamberlain MJ
    Can Med Assoc J; 1978 Aug; 119(3):229-36. PubMed ID: 679127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Familial hemochromatosis. Physiologic studies in the precirrhotic stage of the disease.
    Feller ER; Pont A; Wands JR; Carter EA; Foster G; Kourides IA; Isselbacher KJ
    N Engl J Med; 1977 Jun; 296(25):1422-6. PubMed ID: 194151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for hemochromatosis in asymptomatic subjects with or without a family history.
    Powell LW; Dixon JL; Ramm GA; Purdie DM; Lincoln DJ; Anderson GJ; Subramaniam VN; Hewett DG; Searle JW; Fletcher LM; Crawford DH; Rodgers H; Allen KJ; Cavanaugh JA; Bassett ML
    Arch Intern Med; 2006 Feb; 166(3):294-301. PubMed ID: 16476869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial hemochromatosis: characteristics of the precirrhotic stage in a large kindred.
    Rowe JW; Wands JR; Mezey E; Waterbury LA; Wright JR; Tobin J; Andres R
    Medicine (Baltimore); 1977 May; 56(3):197-211. PubMed ID: 870791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hereditary hemochromatosis. Diagnosis in siblings and children.
    Edwards CQ; Carroll M; Bray P; Cartwright GE
    N Engl J Med; 1977 Jul; 297(1):7-13. PubMed ID: 865566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Idiopathic hemochromatosis: current problems in diagnosis and therapy].
    Fehr J
    Schweiz Med Wochenschr; 1979 Apr; 109(17):633-9. PubMed ID: 441715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemochromatosis: genetic or alcohol-induced?
    LeSage GD; Baldus WP; Fairbanks VF; Baggenstoss AH; McCall JT; Moore SB; Taswell HF; Gordon H
    Gastroenterology; 1983 Jun; 84(6):1471-7. PubMed ID: 6840475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disorders of iron metabolism.
    Nimeh N; Bishop RC
    Med Clin North Am; 1980 Jul; 64(4):631-45. PubMed ID: 6995727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular pool of transient ferric iron, chelatable by deferoxamine and distinct from ferritin, that is involved in oxidative cell injury.
    Rothman RJ; Serroni A; Farber JL
    Mol Pharmacol; 1992 Oct; 42(4):703-10. PubMed ID: 1435746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DIFFERENTIAL FERRIOXAMINE TEST FOR MEASURING CHELATABLE BODY IRON.
    FIELDING J
    J Clin Pathol; 1965 Jan; 18(1):88-97. PubMed ID: 14247711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy.
    Bring P; Partovi N; Ford JA; Yoshida EM
    Pharmacotherapy; 2008 Mar; 28(3):331-42. PubMed ID: 18294113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic zinc in hemochromatosis.
    Adams PC; Bradley C; Frei JV
    Clin Invest Med; 1991 Feb; 14(1):16-20. PubMed ID: 2040101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Idiopathic hemochromatosis--diagnosis and therapy].
    Schmidt U; Preu E; Tuschy U; Senf L; Herre K
    Z Gesamte Inn Med; 1984 Apr; 39(8):152-60. PubMed ID: 6730591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic iron clearance from serum in treated hemochromatosis.
    Batey RG; Pettit JE; Nicholas AW; Sherlock S; Hoffbrand AV
    Gastroenterology; 1978 Nov; 75(5):856-9. PubMed ID: 700326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Removal of non-transferrin-bound iron from blood with iron overload using a device with immobilized desferrioxamine.
    Ambrus CM; Stadler I; Toumbis CA; Stadler A; Anthone S; Anthone R; DeAlarcon P; Deshpande G; Conway J; Vladutiu AO; Ambrus JL
    J Med; 1999; 30(3-4):211-24. PubMed ID: 17312675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hereditary hemochromatosis: laboratory evaluation.
    Moyer TP; Highsmith WE; Smyrk TC; Gross JB
    Clin Chim Acta; 2011 Aug; 412(17-18):1485-92. PubMed ID: 21510925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.